Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis
Open Access
- 7 June 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 10 (1), 57
- https://doi.org/10.1186/1741-7015-10-57
Abstract
Corticosteroids are standard treatment for patients with multiple sclerosis experiencing acute relapse. Because dyspeptic pain is a common side effect of this intervention, patients can be given a histamine receptor-2 antagonist, proton pump inhibitor or antacid to prevent or ameliorate this disturbance. Additionally, patients with multiple sclerosis may be taking these medications independent of corticosteroid treatment. Interventions for gastric disturbances can influence the activation state of the immune system, a principal mediator of pathology in multiple sclerosis. Although histamine release promotes inflammation, activation of the histamine receptor-2 can suppress a proinflammatory immune response, and blocking histamine receptor-2 with an antagonist could shift the balance more towards immune stimulation. Studies utilizing an animal model of multiple sclerosis indicate that histamine receptor-2 antagonists potentially augment disease activity in patients with multiple sclerosis. In contrast, proton pump inhibitors appear to favor immune suppression, but have not been studied in models of multiple sclerosis. Antacids, histamine receptor-2 antagonists and proton pump inhibitors also could alter the intestinal microflora, which may indirectly lead to immune stimulation. Additionally, elevated gastric pH can promote the vitamin B12 deficiency that patients with multiple sclerosis are at risk of developing. Here, we review possible roles of gastric acid inhibitors on immunopathogenic mechanisms associated with multiple sclerosis.Keywords
This publication has 128 references indexed in Scilit:
- Role of the innate immune system in the pathogenesis of multiple sclerosisJournal of Neuroimmunology, 2010
- C5a receptor‐deficient dendritic cells promote induction of Treg and Th17 cellsEuropean Journal of Immunology, 2010
- Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical ImplicationsDigestive Diseases and Sciences, 2009
- The T‐cell pool is anergized in patients with multiple sclerosis in remissionImmunology, 2008
- Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulationImmunological Reviews, 2008
- T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosisImmunology, 2008
- The Th17–ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune diseaseThe Journal of Experimental Medicine, 2008
- Anti‐ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2‐bias in their offspringThe FASEB Journal, 2007
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995